Zoetis (ZTS)
(Delayed Data from NYSE)
$190.03 USD
-0.96 (-0.50%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $189.97 -0.06 (-0.03%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$190.03 USD
-0.96 (-0.50%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $189.97 -0.06 (-0.03%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth F Momentum F VGM
Zacks News
GRFS or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GRFS vs. ZTS: Which Stock Is the Better Value Option?
Company News for Feb 14, 2024
by Zacks Equity Research
Companies in The News Are: ZTS,MAR,ECL,HAS
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Zoetis' (ZTS) Q4 Earnings Miss Expectations, Sales Beat
by Zacks Equity Research
Zoetis (ZTS) reports mixed fourth-quarter results, wherein earnings miss estimates while revenues beat the same.
Compared to Estimates, Zoetis (ZTS) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Zoetis (ZTS) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zoetis (ZTS) Q4 Earnings Lag Estimates
by Zacks Equity Research
Zoetis (ZTS) delivered earnings and revenue surprises of -6.77% and 1.04%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Drug, Biotech Stocks' Q4 Earnings Due on Feb 13: BIIB, ZTS & INCY
by Zacks Equity Research
Let's take a look at three biotech/drug companies, BIIB, ZTS, and INCY, slated to release quarterly results on Feb 13.
Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis' (ZTS) higher companion animal product sales are expected to have driven revenues in the fourth quarter of 2023, partially offset by declining livestock product sales.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Ahead of Zoetis (ZTS) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Zoetis (ZTS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.
Will Sage Therapeutics, Inc. (SAGE) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Sage Therapeutics, Inc. (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zoetis (ZTS) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GRFS or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GRFS vs. ZTS: Which Stock Is the Better Value Option?
Will Zoetis (ZTS) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
GRFS vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
GRFS vs. ZTS: Which Stock Is the Better Value Option?
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
GRFS or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GRFS vs. ZTS: Which Stock Is the Better Value Option?
Should You Invest in the VanEck Agribusiness ETF (MOO)?
by Zacks Equity Research
Sector ETF report for MOO
The Zacks Analyst Blog Highlights Invitation Homes, Choice Hotels International, Zoetis and Owens Corning
by Zacks Equity Research
Invitation Homes, Choice Hotels International, Zoetis and Owens Corning are part of the Zacks top Analyst Blog.
4 Stocks to Watch That Recently Declared Dividend Hikes
by Ritujay Ghosh
Invitation Homes Inc. (INVH), Choice Hotels International, Inc. (CHH), Zoetis Inc. (ZTS) and Owens Corning (OC) recently announced dividend hikes.
GRFS vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
GRFS vs. ZTS: Which Stock Is the Better Value Option?
Here's What Key Metrics Tell Us About Zoetis (ZTS) Q3 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for Zoetis (ZTS) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zoetis' (ZTS) Q3 Earnings Beat, Revenues Miss by a Whisker
by Zacks Equity Research
Zoetis' (ZTS) third-quarter 2023 earnings surpass estimates. However, revenues fall marginally short. The strong performance of the companion animal portfolio drives year-over-year revenues.
Analysts Estimate Sage Therapeutics, Inc. (SAGE) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Sage Therapeutics, Inc. (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.